"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
(→Our Sponsors) |
||
| Line 27: | Line 27: | ||
*Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] | *Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] | ||
*Takara [http://www.takarabioeurope.com/ [Link]] | *Takara [http://www.takarabioeurope.com/ [Link]] | ||
| - | * | + | *Clonetech [http://www.clontech.com/ [Link]] |
*Promega [http://www.promega.com/ [Link]] | *Promega [http://www.promega.com/ [Link]] | ||
*Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | *Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | ||
Revision as of 08:58, 22 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Lluis M. Mir
- Karim Benihoud
INSERM U872
- Srinivas Kaveri
AnyGenes
- Benyoussef Naimi
Our Sponsors
- Embassy of France in Washington [Link]
- Eurogentec [Link]
- Takara [Link]
- Clonetech [Link]
- Promega [Link]
- Sigma-Aldrich [Link]
- Qiagen [Link]
- Fisher-Scientific [Link]
